Lapatinib blocks ligand-activated signaling from multiple receptor combinations, including homo-and heterodimers of EGFR and HER2 [5]; preclinically, it inhibits the proliferation of trastuaumab-resistant cancer cells [2], [6]. Here, ERBB2 is linked to cancer.